MAP4 expression was significantly associated with subtype (χ2 = 45.528, df = 5, P = 1.1332E−8), grade (χ2 = 14.209, df = 2, P = 0.001), stage (χ2 = 15.050, df = 3, P = 0.002), residual disease (χ2 = 9.965, df = 1, P = 0.007) and tumour response to taxane-containing chemotherapy (χ2 = 4.596, df = 1, P = 0.032; high MAP4 expression associated with chemo-sensitisation). This evidence concerns the gene MAP4 and neoplasm.